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Abstract
Background: The valuable clinical data, specimens, and assay results collected during a primary clinical trial or
observational study can enable researchers to answer additional, pressing questions with relatively small
investments in new measurements. However, management of such follow-on, “ancillary” studies is complex. It
requires coordinating across institutions, sites, repositories, and approval boards, as well as distributing, integrating,
and analyzing diverse data types. General-purpose software systems that simplify the management of ancillary
studies have not yet been explored in the research literature.
Methods: We have identified requirements for ancillary study management primarily as part of our ongoing work with
a number of large research consortia. These organizations include the Center for HIV/AIDS Vaccine Immunology (CHAVI),
the Immune Tolerance Network (ITN), the HIV Vaccine Trials Network (HVTN), the U.S. Military HIV Research Program
(MHRP), and the Network for Pancreatic Organ Donors with Diabetes (nPOD). We also consulted with researchers at a
range of other disease research organizations regarding their workflows and data management strategies. Lastly, to
enhance breadth, we reviewed process documents for ancillary study management from other organizations.
Results: By exploring characteristics of ancillary studies, we identify differentiating requirements and scenarios for
ancillary study management systems (ASMSs). Distinguishing characteristics of ancillary studies may include the
collection of additional measurements (particularly new analyses of existing specimens); the initiation of studies by
investigators unaffiliated with the original study; cross-protocol data pooling and analysis; pre-existing participant
consent; and pre-existing data context and provenance. For an ASMS to address these characteristics, it would need to
address both operational requirements (e.g., allocating existing specimens) and data management requirements (e.g.,
securely distributing and integrating primary and ancillary data).
Conclusions: The scenarios and requirements we describe can help guide the development of systems that make
conducting ancillary studies easier, less expensive, and less error-prone. Given the relatively consistent characteristics
and challenges of ancillary study management, general-purpose ASMSs are likely to be useful to a wide range of
organizations. Using the requirements identified in this paper, we are currently developing an open-source,
general-purpose ASMS based on LabKey Server (http://www.labkey.org) in collaboration with CHAVI, the ITN and nPOD.
Background
Ancillary studies allow researchers to leverage the high-
value data collected as part of a primary clinical trial or
observational study, augment this data with additional
measurements, and answer questions that were not part
of the primary study design [1]. For example, an ancil-
lary study might identify the characteristics of individual
immune responses or viral types that contribute to
vaccine failure or success, elucidate mechanisms of treat-
ment response, or identify biomarkers associated with
positive outcomes. Results from such studies can ad-
vance translational research and point the way to better
treatments and trials. Ancillary studies can provide these
benefits in a cost-effective manner because the bulk of
study data has already been collected and, typically, the
primary study has already shown a result worthy of fur-
ther investigation.
The National Institute of Health (NIH) considers stu-
dies that reuse clinical trial or observational study data
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numerous, ongoing grant mechanisms [2-9] for funding
them. Searching PubMed for the term “ancillary study”
and its plural produces 910 results ([10], December
2012). A recent review of the emerging field of clinical
research informatics identifies secondary data use as a
key pain point [11,12]. From a broader perspective, reuse
of scientific data has become a priority and a concern
across fields of all science, not just biomedical research
studies [13,14].
For primary studies and trials, clinical trial manage-
ment systems (CTMSs) are widely used to enhance effi-
ciency, reduce costs, comply with regulations, and speed
up data analysis. Today, researchers have a wide range of
CTMS options at their disposal, from proprietary solu-
tions such as Oracle Corporation’s Phase Forward Clin-
trial [15] and Oracle Clinical [16] and to open source
solutions such as TrialDB [17] and OpenClinica [18,19].
CTMSs are actively studied and developed by the aca-
demic community [20-24].
In contrast, with the exception of our own conference
abstract [25], the research literature contains little discus-
sion of systems (or system extensions) that specifically ad-
dress the cradle-to-grave needs of ancillary studies. The
open source i2b2 system (Informatics for Integrating Biol-
ogy and the Bedside) [26-28] is particularly noteworthy for
its support for de-identified cohort discovery across feder-
ated patient information repositories. However, descrip-
tions of i2b2 focus primarily on the repurposing of
information and material by-products of health care deli-
very [26-29], not on the full set of scenarios surrounding
reuse of the products of trials and studies.
Given the importance, cost-effectiveness and preva-
lence of ancillary studies, as well as the wide use of
CTMSs, it is surprising that general-purpose ancillary
study management systems (ASMSs) have not been dis-
cussed in the research literature, either as stand-alone
systems or as extensions to CTMSs. Just like CTMSs,
ASMSs have the potential to ease the cost, administra-
tive burden, and expertise required to execute ancillary
studies. Given this potential, here we review the core
scenarios that a general-purpose ASMS should support
to provide the greatest benefits. We focus specifically on
differentiating requirements for managing ancillary study
data (vs. primary study data) to illustrate how the
requirements for an ASMS extend beyond those of pri-
mary study management systems.
Our analysis is based upon our ongoing work to build
an open-source, general-purpose ASMS based on Lab-
Key Server [30-33] in collaboration with thee large
disease research networks: (i) the Center for HIV/AIDS
Vaccine Immunology (CHAVI) [34], (ii) the Immune
Tolerance Network (ITN) [35,36], and (iii) the Juvenile
Diabetes Research Foundation (JDRF) Network forPancreatic Organ Donors with Diabetes (nPOD) [37-39].
General-purpose ASMS features are being built into the
LabKey Server platform, so they are available in all
updated instances of the system. Installations of LabKey
Server that currently support our ASMS collaborators
include the Atlas Science Portal and ITN TrialShare.
The Atlas Science Portal [30,40] is customized and
maintained by the Statistical Center for HIV/AIDS
Research and Prevention (SCHARP) at the Fred Hutch-
inson Cancer Research Center (FHCRC) to support
multiple HIV research networks, including CHAVI. ITN
TrialShare [41] is customized and maintained by the
ITN to support data sharing and collaboration among
immunology researchers within and beyond the ITN.
nPOD is currently setting up its own LabKey Server to
support ancillary studies performed on its repository of
high-value specimens from Type 1 diabetes donors.
Our investigation also benefited from assisting the
HIV Vaccine Trials Network (HVTN) [42] and the U.S.
Military HIV Research Program (MHRP) [43] in their
efforts to develop custom, organization-specific tools for
managing the operations of ancillary studies. These tools
are built into the Atlas Science Portal.
Examples of ancillary studies currently being con-
ducted by our collaborators include work to discover
transplant rejection biomarkers (e.g., genomic studies of
liver allograft rejection and recurrent hepatitis C disease
[44]), identify and investigate individuals with excep-
tional responses to infection (e.g., CHAVI’s studies of
“elite controllers” of HIV [45]); examine whether HIV
vaccines exert selection pressure on viral sequences (e.g.,
the HVTN’s studies of vaccine recipients who became
infected in the STEP trial [46]); and explore potential
correlates of protection in HIV vaccine recipients (e.g.,
the HVTN’s investigations of the STEP trial and the
MHRP’s work on the Thai Phase III trial, also known as
RV144 [47]).
Methods
We identified requirements for ancillary study manage-
ment primarily as part of our ongoing work with CHAVI,
ITN, nPOD, HVTN, MHRP, and SCHARP. SCHARP is
the data management center for CHAVI, HVTN, the Col-
laboration for AIDS Vaccine Discovery (CAVD), the HIV
Prevention Trials Network (HPTN), and the Microbicide
Trials Network (MTN). This work includes developing
tools for HVTN and MHRP to facilitate operational
management of the RV144 immune correlates study, a
large-scale ancillary study that includes over 45 sub-
studies.
We also consulted with researchers at a variety of
disease research organizations regarding their workflows
and data management strategies, including: CHAVI,
ITN, nPOD, HVTN, SCHARP, MTN, HPTN, CAVD,
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Northwest Prostate Cancer Specialized Program of Re-
search Excellence (SPORE). Lastly, we reviewed process
documents for ancillary study management from a
variety of other organizations to increase the breadth of
our review [48-57].
The organizations we consulted manage large numbers
of trials and studies all over the globe. For example, as
of August 2011, the ITN had 42 active primary trials
and numerous ancillary trials taking place at 158 domes-
tic and 10 international sites. CHAVI had 5 active pri-
mary studies and several ancillary studies running at 14
sites worldwide. The HVTN had over 54 active primary
studies and several large-scale ancillary studies taking
place at over 40 sites in the U.S. and internationally. The
HPTN had 18 active primary studies and 5 active ancil-
lary studies taking place at over 45 sites worldwide. As
of August 2012, nPOD reported that 82 ancillary studies
at 59 different universities were using specimens from
its repository [58].
The process we used to define and verify ancillary
study management scenarios and requirements was
deliberatively iterative. We conducted repeated inter-
views with collaborators working with representative
organizations, particularly CHAVI, ITN, HVTN,
MHRP, SCHARP, HPTN and MTN. We provided writ-
ten copies of the scenarios and requirements distilled
from these interviews to interviewees at these organi-
zations. After individuals reviewed these written mate-
rials, we conducted follow-up interviews and updated
the written scenarios and requirements to reflect
detailed feedback. The ITN, HVTN, MHRP and
SCHARP collaborators participating as co-authors
provided written sign-off on the final set of scenarios
and requirements. We are concretely validating these
scenarios and requirements as we develop the ancillary
study management features of LabKey Server and ver-
ify these features with researchers using the system to
conduct ancillary studies.
Results
Differentiating characteristics of ancillary studies
Several qualities generally distinguish ancillary studies
from typical clinical trials or studies of other types.
These characteristics produce different core require-
ments for an ASMS than for a primary study manage-
ment system. Some of these characteristics may exist for
both types of systems; however, taken together, they are
not typical for primary studies, so their associated
requirements are not ordinarily satisfied by existing
systems.
Collection of additional measurements. “Ancillary
studies” are most commonly defined as secondary orexploratory studies that were not included in the pri-
mary study plan and require the collection of additional
measurements [1]. The term “ancillary studies” may
sometimes be broadened to encompass “secondary data
analysis” [59]. Secondary data analysis does not involve
further measurements [1], just the reanalysis of existing
data. Colloquially, many terms may refer to ancillary
studies, including “freezer studies” (because frozen speci-
mens are used), “sub-studies” and “special emphasis
studies.”
For our collaborators and the groups we consulted,
collection of additional measurements typically means
performing additional analyses on existing specimens
from a primary study. Using existing, frozen speci-
mens poses thorny challenges in locating, confirming
consent, allocating, and transporting specimens to a
range of labs for a multiplicity of assays. For example,
as of August 2011, MHRP’s ongoing RV144 immune
correlates ancillary study already involves over 100
different assays being performed at more than 40
separate labs.
For certain organizations, the collection of additional
data as part of an ancillary study may also involve fur-
ther clinical visits, clinical procedures, and/or collection
of specimens. However, when a study requires new vis-
its, procedure or specimens, it starts to share many char-
acteristics (and requirements) of a primary study. For
this reason, we focus here on ancillary studies that in-
volve simply the analysis of frozen, existing specimens.
This type of ancillary “freezer” study has informatics
requirements most clearly different than a primary study
and, in our experience, is the most common type of
ancillary study.
Conduct of a study by external investigators. De-
pending on the organization, ancillary studies may be
proposed by investigators who participated in the ori-
ginal study, or by researchers fully external to the pro-
ject. After approval, studies may be run independently
by external investigators, internally by the primary study
organization, or collaboratively by a mix of both.
Management of data and operations is more complex
when an external team runs all or parts of the ancillary
study. Internal investigators can leverage the original study’s
staff and systems possibly while the original study is on-
going. In contrast, external investigators face process- and
technology-based barriers to getting primary study informa-
tion and specimens; correctly interpreting primary data; en-
suring data security; and contributing their results back to
the primary study repository.
Pre-existing data context and provenance. Tracking
and retention of data context (e.g., participant enroll-
ment criteria, study location, etc.) and provenance
(e.g., which piece of data came from which source or
study, which quality control or processing steps have
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studies. If context and provenance information for a
primary study are inaccessible, it may be impossible to
reuse the study’s data correctly.
Cross-protocol data pooling and analysis. Ancillary
studies often involve the comparison of cohorts who
experienced different treatment protocols in separate
primary trials, or pooling of subsets of participants
across different primary studies for use in new analyses.
Both of these techniques require tagging groups of parti-
cipants across studies, and aligning and integrating data
for these participants across protocols.
In order to integrate data across protocols, it may be
necessary to reconcile differences in data representation
across studies. For example, different laboratories may
have used different controlled terminologies to record
results in different studies. Context and provenance in-
formation are also needed to judge and/or enhance the
comparability of pooled data.
Cross-study data reconciliation and integration can be
even more challenging when each relevant primary study
has been performed by a different organization, each
with its own data management system and standards for
data representation.
Pre-existing and new participant consent. Partici-
pants in the original trial may or may not have provided
their consent for inclusion of their data and specimens
in an ancillary study. Even when they have consented to
reuse of certain types of data and specimens collected
from them, they may not have consented to the reuse of
all types for all purposes. For example, genetic analysis
may be prohibited or not specifically included in the
consent. This means that study managers may need to
track down existing consent forms (and any revisions) to
determine whether consent is sufficient, or whether fur-
ther consent is needed.Existing alternatives for managing ancillary studies
Today, three strategies for ancillary study management
seem to be most commonly employed: (i) using a CTMS
for the aspects of ancillary studies that the tool can sup-
port (ii) using an ad hoc combination of software for
project management, plus a second, separate tool for
data management and a third tool for specimen requests
and tracking or (iii) developing of custom, organization-
specific, end-to-end systems. These three strategies are
discussed here due to the frequency of their use, but
they are not necessarily comparable, particularly for
real-time study management for multicenter projects.
For example, an ad hoc solution is unlikely to achieve
the same level of data safety, reliability, consistency and
management efficiency as a centralized, web-based infor-
mation system.i. CTMSs. A CTMS that successfully manages a pri-
mary clinical trial or observational study may not be
well-suited to support ancillary study management. First
and foremost, a CTMS may not be designed to support
cross-study data pooling. Few existing CTMSs mention
cross-protocol or cross-study analysis in their documen-
tation. Furthermore, certain ancillary study data manage-
ment scenarios (such as populating an ancillary study
with primary data) are not typically required for the
completion of a primary clinical trial or study, so they
may not be supported. In direct opposition to ancillary
study investigators’ need to accumulate new data, Good
Clinical Data Management Practice (GCDMP) calls for
the clinical trial database to be locked upon completion
of the trial [60,61], so data cannot easily be added. Also,
a CTMS may not be designed to manage or provide data
access to external investigators who wish to initiate an-
cillary studies.
iia. Project management tools. Software such as
Excel, Microsoft Project, Microsoft SharePoint, email
and FTP can be used to support the operational side of
ancillary study management. However, employing a var-
iety of tools in concert can be more complex than using
an end-to-end solution that spans common scenarios for
ancillary study management. Many (though not all) pro-
ject management tools lack support for multi-user col-
laboration. Furthermore, some tools do not “scale up”
well. For example, managing projects in Excel is straight-
forward for small projects, but harder for large studies
with thousands of subjects, multiple project managers
and many participating institutions.
iib. Data management tools. In our review, SAS was
mentioned most often as the tool used for managing and
analyzing data in ancillary studies; however, extracting
data with SAS requires programming expertise. STATA,
SPSS and R were also mentioned [62], but these also re-
quire programming expertise. Excel and Access do not
require extensive programming expertise; however, they
do not inherently understand study concepts (such as
visits, participants, and cohorts) or relationships between
these concepts. Furthermore, these tools can pose chal-
lenges in scalability, multi-user access, and security.
We have previously reviewed open source systems for
managing and integrating clinical and experimental data
types; however, none of these platforms addresses the
particular needs of ancillary studies [30]. Pietrobon et al.
described a suite of tools for secondary analysis of study
data, but these are intended for use in a manner fully ex-
ternal to the original study; furthermore, they focus on
publicly available data [63].
Proprietary software systems for data integration (e.g.,
Oracle Life Sciences Data Hub [64] and SAS Clinical
Data Integration [65]) certainly exist. The Oracle and
SAS offerings are notable for their emphasis on cross-
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systems have a number of limitations, including vendor
lock-in, lack of transparency, limited extensibility, and
cost, as we have reviewed previously [30].
iic. Specimen request tracking tools. Specialized
tools, such as BSI (Biological Specimen Inventory Sys-
tem) [66] or Freezerworks [67], can be used for speci-
men management; however, they may not integrate
smoothly with other systems involved in data and speci-
men management.
iii. Custom systems. Organization-specific solutions
may range from integrated suites of common tools (e.g.,
SAS datasets and programs used in conjunction with
DataFax) to single-purpose systems built from the
ground up to meet an organization’s particular needs.
Such solutions can be completely satisfactory for ancil-
lary studies, but may require programming expertise
(often SAS), or entail high development costs.
Some proprietary systems (e.g., Labmatrix from Bio-
Fortis [68]) provide support for certain ancillary study
scenarios (particularly the exploration of existing data
and specimens). However, it is difficult to evaluate how
well such systems support the full operational and data
management workflows of ancillary studies given the
limited documentation publicly available for them.Key scenarios for ancillary study management
The steps described in this section provide a representa-
tive (but certainly not universal) workflow for ancillary
study management. To focus the discussion, we consider
a “freezer study” workflow, where existing specimens
undergo additional analysis, but no new specimens or
clinical data are collected. Our collaborators are most
commonly concerned with this kind of ancillary study.
This type of ancillary study is particularly illustrative of
how the requirements for managing ancillary studies
extend beyond those of either primary studies or sec-
ondary data analysis.
For each step in this workflow, we describe scenarios
where the support of an ASMS would be particularly
valuable. Table 1 provides an overview of the steps and
highlights the scenarios and requirements that most dif-
ferentiate the needs of an ancillary study from those of a
primary study. Figure 1 shows how data might flow to/
from an ASMS for this workflow. Figure 2 shows two
kinds of feedback loops (“virtuous circles”) implied by
this workflow that could be facilitated by an ASMS.
Any organization executing these kinds of ancillary
studies would have its own unique workflow, using these
steps to varying degrees and in varying order, so an
ASMS would need to be sufficiently flexible to accom-
modate this variability. Nevertheless, our review revealed
surprising consistency in scenarios, likely due to theuniformity of regulatory funding requirements and pub-
lished best practices.
An ASMS could support only some of the steps in this
workflow and still provide value. We heard repeatedly
that disease research organizations want tools that can
complement and seamlessly integrate with existing sys-
tems that already support certain scenarios, not replace
all existing infrastructure. Workflow requirements that
differentiate ancillary study management (highlighted in
Table 1) are least likely to be covered well by existing
tools.
In addition to facilitating the individual steps in this
workflow, an ASMS might also facilitate overall project
management for organizations facing a proliferation of
ancillary studies. For example, an ASMS might track sta-
tus and metadata for all of an organization’s ancillary
studies; provide live summary dashboards for progress,
materials and issues; and deliver notification emails upon
completion of key steps.
1. Hypothesis generation. This may take place at any
point from initiation of the primary study onwards. It
requires access to data and data context information,
plus tools for making sense of information that may
come from multiple studies.
The more broadly primary study data and context in-
formation can be made available in an accessible form,
the broader the pool of investigators that can bring ideas
to bear. Providing secure access to primary study data-
sets, analysis tools and curated materials (e.g., related
manuscripts) could attract potential investigators to
areas of interest to the sponsoring organization. The
greater an investigator’s access to such information, the
more insightfully the researcher will be able to formulate
hypotheses.
When exploring a potential hypothesis, when evaluating
a proposal’s feasibility (Step 2), or when an ancillary study
proposal and/or protocol has been accepted, relevant sub-
jects, specimens and data must be identified across a range
of data sources, often including multiple primary studies.
To review participants for inclusion in an ancillary study,
investigators need to align, integrate and evaluate a range
of data types, including consent, clinical, assay, and speci-
men. To evaluate which types of data are comparable
across studies, investigators need to access context and
provenance information from the primary study. They also
need to determine the availability, quantities, and quality
of relevant specimens. The deeper the investigation pos-
sible at this stage, the less likely that a study will later be
proven infeasible due to a lack of available participants
meeting protocol requirements, or missing data, speci-
mens, or consent.
To identify relevant participants and materials, research-
ers and administrators need tools for applying set theory
relationships (e.g., set difference, intersection, union,
Table 1 Differentiating requirements for a representative ancillary study workflow
Step # Step Name Key Differentiating Requirements
1 Hypothesis generation a. Identify interesting categories of participants from primary study
b. Access existing data and specimen information for those participants
c. Provide sufficient information to external investigators for them to propose ancillary studies
2 Proposal review a. Review availability of existing specimens
b. Review priorities for use of remaining specimens, possibly reserving specimens
c. Evaluate overlap and comparability of existing data and proposed measurements/analyses
3 Creation of protocol or plan a. Decide which existing participant data and specimens to use.
b. Plan expectations for collecting new ancillary data complementary to existing primary data
4 Consent verification or acquisition a. Determine whether consent exists and is sufficient for desired analyses
b. Obtain additional consent if necessary
5 Retrieval of existing data a. Compile relevant subset of primary study data required for the ancillary study
b. If external investigators are leading the ancillary study, share this subset of data with them.
6 Delivery and analysis of specimens a. Request, locate, ship and track existing specimens, as well as manage
material transfer agreements
b. Maintain identifiers relevant to primary study during further specimen analysis
7 Data integration a. Retain context and provenance from both primary and ancillary studies, including processing
and quality control information
b. Retain origination information (primary vs. ancillary)
c. Resolve differences (representation, quality control, etc.) and join ancillary and primary data
8 Data/specimen repatriation a. Contribute ancillary study data (raw and/or processed) back to the primary study
b. Retain data context, provenance, processing and other metadata from ancillary study
c. Return unused specimens
9 Publication a. Coordinate preparation and review of publications across primary and ancillary investigators
This table calls out the key differentiating requirements for each step in the ancillary study workflow described in this paper. It aims to clarify how
ancillary study requirements extend beyond those of primary studies and secondary data analysis. Note that this workflow addresses the “freezer
study” scenario, where the ancillary study’s additional measurements come from analysis of existing specimens, not collection of new specimens or
clinical data.
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combining, and visualizing diverse data types in a way that
facilitates comparisons between participants. Ideally, study
administrators should be able to select participants and
datasets from multiple studies, align measurements across
datasets and investigate these datasets without program-
ming. Data reviewers also need a tagging system to keep
track of participant groupings and designations, such as
participants with relevant characteristics, for inclusion in
study cohorts.
2. Proposal review. In this step, an investigator sub-
mits a proposal that complies with the specific guide-
lines of the organizations sponsoring and conducting the
primary study. This proposal typically describes the goals
and relevance of the study; schedule expectations; gen-
eral profiles of participants desired for the study; types
of clinical data needed; labs or sites that expect to par-
ticipate in the study; whether new clinical data or speci-
mens are needed; whether existing specimens are
required; the minimum specimen quantities necessary
for analysis; plans for additional assays on specimens;
any burden of analytical support that might fall on theoriginal study’s data management and statistics team;
and funding sources for external investigators and any
internal support they require.
Proposals are vetted by the leadership of the original
study (including specimen managers and statisticians), a
range of review boards (e.g., institutional review boards
(IRBs)), funders, federal regulatory or sponsoring agen-
cies, and participating clinic sites. If changes in a pro-
posal are needed later (e.g., additional participant data
are required), further review by these bodies may be
necessary.
To perform satisfactory reviews of proposals, the team
that sponsored the original study may need to review
the data and unused specimens from that study, plus
any competing requests for these specimens. That means
that this information needs to be accessible, reviewable,
and shareable in a secure manner. Tools that support
data and specimen investigation and review (described
in Step 1) may also be valuable here.
The breadth, diversity, and ongoing nature of review
for ancillary study proposals mean that the review

































Figure 1 ASMS data flows. This figure shows a conceptual model for data flows for ancillary studies whose primary focus is analysis of stored
specimens. In this scenario, data flows into the ASMS from the primary study’s CTMS (which contains information on participants, visits, consent
and other pre-existing data) and specimen repository LIMSs (Laboratory Information Management Systems, which contain information on stored
specimens available for further investigation). Before an ancillary study is initiated, the ASMS is used for hypothesis generation and feasibility
investigations based on specimen availability. Once a particular ancillary study has been identified, a container for its data is established within
the ASMS. After the ancillary study has been approved, any additional participant consents required for the study are collected by clinical sites
and noted in the ASMS. Requests for needed specimens (including material transfer agreements) are sent to the appropriate specimen
repositories, which in turn send stored specimens to appropriate labs. The labs perform assays on the specimens and import the results to the
ancillary study container in the ASMS. Once the ancillary study is complete, results may be repatriated to the primary study. Results may also be
shared in publications or other venues.
This model presumes that all data for the ancillary study is managed within the ASMS, not the CTMS or an external system. It also presumes that
external investigators can be given access to the study within the ASMS. Under different assumptions, usage patterns and data flows would
change, but an ASMS could still prove helpful.
For example, if gathering new clinical data from study participants is a significant piece of an ancillary study, using an organization’s existing
CTMS for collecting and managing clinical data might make the most sense. An ASMS could still be desirable for other aspects of the study. For
our collaborators, CTMSs have not proven amenable to the kinds of queries necessary for hypothesis generation and participant identification.
Also, they are not ordinarily well-integrated with relevant LIMSs, so they do not facilitate identification of specimen availability. An ASMS could be
used for these steps and others that are not typically supported by CTMSs or LIMSs, such as specimen requests and assay data management.
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requesting, tracking, and delivering materials, plus track-
ing the approval process and determining the status of
applications.
3. Creation of protocol or plan. The trial protocol or
observational study plan sets out the research hypoth-
esis, existing specimens, and new assays that are
required, as well as data analysis and delivery expecta-
tions. Sometimes this document must be included in
the original proposal that is reviewed in Step 2. How-
ever, earlier development of a complete protocol may
not be possible when an external investigator lacks ac-
cess to the data, context, specimens, and statisticians
associated with the original study. Tools for providing
limited access earlier in this process could reduce later
iteration on proposals and protocols.No matter when a protocol or proposal is developed,
it will need to be tracked and made available to people
involved in both new and original studies, ideally on a
secure, restricted web site. It may also need to undergo
further formal review and approval, so Step 2 may be
repeated.
If analysis of existing specimens is needed, statisti-
cians or scientists associated with the original study
may provide investigation and guidance on which
sets of samples to use. Communication of informa-
tion between internal and external contributors at this
stage might be facilitated by a secure, mutually ac-
cessible ASMS.
Tool support from an ASMS would also aid study
design and expectation tracking. Both study design and
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Figure 2 Virtuous cycle feedback loops. Using existing results and materials to refine hypotheses and develop new insights can produce
“virtuous cycles,” where the research efforts of today feed tomorrow’s discoveries. Figure 2 shows two kinds of such cycles that are implied by
the ancillary study workflow described here. An ASMS can facilitate both types of cycles by smoothing the flow of information, enabling
collaboration, simplifying workflows and allowing researchers to make the most of existing materials and information.
(i) Full study cycle. The nine steps in the ancillary study workflow form a virtuous cycle that spans the full life of a study, from the first glimmer
of an idea through publication. For simplicity, Figure 2 breaks these steps into three phases (study initiation, study execution, and results sharing).
These steps are roughly equivalent to those that form the “inner,” study-based loop in Kahn and Weng’s conceptual model for clinical research
informatics [96]. In such cycles, published hypotheses and shared data from completed studies are used to generate future discovery cycles by
providing inspiration and ingredients for follow-up studies.
(2) Incremental review cycles. An ASMS can also facilitate smaller-scale virtuous cycles during all phases of an ancillary study. First and
foremost, during the study initiation phase, the information and tools made available by an ASMS allow incremental refinement of hypotheses
and study plans according to existing data, specimen availability, and consent limitations. During later phases of a study, an ASMS can make it
easier to share and review new information as it is collected, allowing feedback of new insights into study investigations, operations, analyses,
and conclusions. Of course, in-progress studies governed by clinical trial regulations will provide less scope for immediate use of this type of
feedback than the kinds of pre-clinical, exploratory studies common among our collaborators.
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support cross-study planning. A study design tool
allows generation of study plans (e.g., visit/subject/
assay mappings and expectations) from study para-
meters. Expectation tracking tools facilitate scheduling
and tracking steps in a study (e.g., which assay should
be performed when and by which lab). This makes it
easier to identify missed steps and to forecast schedule
risk. Expectation tracking tools are particularly import-
ant when an ancillary study starts mid-way through a
primary study and relies upon data or specimens that
will be collected later in the primary study.
4. Consent verification or acquisition. In order to use
data or specimens from human subjects who participated
in a primary study, investigators must either confirm
consent using pre-existing consent forms or obtain newconsent from participants. Central archiving of consent
forms and/or consent metadata may facilitate determin-
ation of consent, but centralization may not have hap-
pened as part of the primary study.
Electronic management of consent is highly desired
for all types of studies, not just ancillary studies [69],
as are ontology-based definition of consent [70,71] and
collection of metadata about consent coverage. These
enable standardization of consent across network
trials; reduce ambiguity; allow more efficient and con-
sistent determination of consent coverage and status;
increase the likelihood that specimens and data can be
re-used in future studies; and facilitate compliance
with consent agreements that require the destruction
of participant specimens at a particular time or upon
participant withdrawal from any phase of a trial.
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identified and consent is confirmed, existing participant
data records from relevant primary studies must be
retrieved for reuse. Reconciliation of vocabulary (par-
ticularly column, field, visit, and participant identifier
naming) and/or data representations (such as data types,
units and formats) may be necessary to avoid conflicts
and allow eventual integration. Tools that automate re-
naming, aliasing, and/or field parsing can help facilitate
this process. Standardization may be required for all
kinds of data, particularly when there is variation in
study protocols, participant visit schedules, lab instru-
ments, reagents, lab protocols or other aspects of data
collection. Alignment of events or visits across studies
or datasets is usually required for comparisons, but can
be challenging. Both standardization and alignment typ-
ically require the assistance of expert statisticians. Statis-
ticians’ work can be facilitated by tools that make it
easier to draw data from multiple sources; determine
data provenance and context; map visits; and filter, sort,
align, integrate, and visualize the data.
Once data are retrieved, they need to be transmitted to
ancillary study investigators, or external investigators need
to receive access to the data on the sponsoring organiza-
tion’s data systems. Today, when data are transmitted
externally, they are often “thrown over the wall” to exter-
nal investigators via SAS, Excel or text files. Data delivery
may happen via email, which can pose security concerns.
The external investigator then uses Excel, Access, SAS, or
other software to accumulate and analyze results, some-
times completely independently. When primary data are
delivered in a one-time snapshot, corrections to data in
the primary study may not be passed on. Furthermore, the
arms-length strategy can produce downstream challenges
when the sponsoring organization wishes to integrate data
and results from an ancillary study into the primary,
central database. The arms-length strategy also breaks
links to related and/or contextual information, as well as
pre-empting any automatic tracking of data provenance.
Alternatively, it might make more sense to provide ex-
ternal investigators with partial access to the sponsoring
organization’s ASMS. Data formats and standards would
have fewer opportunities to diverge if external investiga-
tors could use the ASMS’s tools, standards, and formats
for managing data records, context, and provenance. An
ASMS could also facilitate management of data transfer
agreements, enforcement of data security restrictions,
and monitoring of external data access.
6. Delivery and analysis of specimens. Samples suffi-
cient for performing the assays required for the study
must be located, requested and shipped to appropriate
labs in the right quantities at the right time for analysis.
Furthermore, as part of the specimen request process, Ma-
terial Transfer Agreements (MTAs) must be exchanged,approved and tracked. Theoretically, these steps can be
managed through email, but structured, secure tools for
specimen requests, tracking and MTA management can
make this process easier. Specimens distributed to external
collaborators for ancillary studies are often re-coded to
provide greater protection of participant confidentiality
and/or to blind collaborators to participant study identi-
fiers (IDs). Maintaining links between primary study IDs
and ancillary study IDs within an ASMS would provide a
central location for this information and later facilitate
data integration (Step 7). Also, formally tracking the sam-
ples used for ancillary analysis would facilitate planning
and executing future, related studies that wish to leverage
“sister” specimen vials.
When a study involves multiple labs and investigators,
tracking and sharing assay results using a multiplicity of
spreadsheets can quickly become unwieldy and lead to
variation in formats and standards. Systems that support
the definition and use of custom assay data types (e.g.,
LabKey Server) can make it easier to collect assay data in
a standard manner and share it efficiently. Such systems
could be particularly helpful when assay harmonization
[72,73] is needed to ensure results are comparable across
labs, investigators and studies.
7. Data integration. After the collection of clinical
data and/or execution of assays, results must be centra-
lized and integrated to allow for comprehensive analyses.
When investigators are external to the primary study,
this process may be entirely external to the team (and
information systems) responsible for the original study.
Receipt of results must be tracked in a manner that
allows administrators to identify remaining and missing
data, including the reason for missing data (e.g., the sub-
ject has passed away or become unreachable). Results
must also be associated with metadata indicating the
processing and quality control steps that have taken
place for the data, or other information necessary for
understanding the context and provenance of the data.
The availability of such information is becoming ever-
more important for weighing the comparability of assay
results thanks to the rapid evolution and growing
complexity of high-throughput experimental techniques
[74-78].
Results from both the original and the new study must
be integrated, so tools should support the combination
of data from multiple studies or protocols. Furthermore,
when data representation differs between primary and
ancillary studies, these differences may need to be recon-
ciled before data can be integrated (as described in Step
5 above). The use of a single data management system
for both primary and ancillary studies may reduce such
divergence, for example through the enforcement of
standardized terminologies and the use of standardized
tools for data acquisition.
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of contributors, from principal investigators to statisticians
to lab scientists who performed the assays. This means that
the system for storing this information should ideally be ac-
cessible to all collaborators and allow them to contribute
their updates back to the system in a manner that tracks
data processing. During the entire process of data integra-
tion, the data must remain secure, so only those authorized
to access particular data sets may view them.
8. Data and specimen repatriation. After the ancil-
lary study reaches completion, data produced by this
study ideally needs to be contributed back to the central
database for the primary study. This allows other investi-
gators to leverage the data for further studies. Left-over
specimens from the ancillary study may also need to be
moved from labs, clinics, and external repositories into
the central specimen repository for the primary study.
This enables easier reuse of such vials in future studies.
However, neither data nor specimen repatriation is
straightforward, and tracking data and specimen proven-
ance can be quite challenging.
We heard significant concerns about the difficulty of
bringing ancillary data into the primary repository. One
organization told us “we may never see the data [again].”
Today, some organizations enforce deposition of ancil-
lary study data into the primary study database quite
strictly. They require receipt of data from the ancillary
study before they release the full set of primary study
data to external investigators [49,51]. For studies where
full datasets from the primary study are required for the
development of ancillary data, this is not practical.
Successful data repatriation requires that data, proven-
ance notations and context information adhere to the
standards and formats of the primary study. When ancil-
lary study data have been managed in systems external to
the systems employed for the primary study, this can be
particularly challenging. Furthermore, information about
data origins (in particular, which data came from the pri-
mary vs. the ancillary study) may no longer be available,
making it hard to integrate ancillary data back into the pri-
mary study without duplicating data. When provenance
information is lost and layers of an ancillary study can no
longer be tracked back to their original sources, resear-
chers run the risk of misunderstanding which data are
comparable. Moreover, when the origins of clinical trial
data are not clearly traceable, the trial may not meet the
FDA’s ALCOA standard (attributable, legible, contempo-
raneous, original, and accurate) [79,80]. An ASMS that
allows management of both primary and ancillary data
could allow standardization of data and metadata collec-
tion throughout the study, as well as retention of data
provenance information and linkages.
A further wrinkle unique to ancillary studies is that data
funded and obtained by external investigators may need tobe marked as embargoed for use by other investigators for
some period of time. Embargo allows the data originators
to produce the first publications reporting their results.
9. Publication. Organizations that permit ancillary
studies to be performed using their data consistently re-
quire an opportunity to review and approve manuscripts
resulting from ancillary studies before the publication.
This is necessary to ensure compliance with regulations
(particularly participant privacy laws) and organizational
policies.
Tracking of manuscripts under consideration and
already published can be sufficiently complex that support
from software tools is desirable. For example, to support
this scenario, the HVTN utilized the Atlas Science Portal
to provide a custom approval workflow for publications
and other documents.Cross-study data pooling, reconciliation and update
scenarios
The need to assemble and integrate data across studies
during ancillary study workflows can pose a key impediment
to using a CTMS alone for ancillary study management. As
a result, cross-study challenges can prove influential in
examining alternatives such as an ASMS. For this reason,
we review how and when cross-study data pooling, recon-
ciliation, and update challenges occur for ancillary studies.
The intended meaning of “cross-study data pooling”
can vary widely in scope and degree of integration at dif-
ferent stages of ancillary study workflows and in differ-
ent organizations. This variation can exert a strong
influence on requirements, so recognizing this range can
help an organization prioritize its informatics needs. The
spectrum of cross-study data pooling scenarios varies
along at least two axes:Scope
 A broad scope of pooling is usually desirable during
hypothesis generation, feasibility analysis, and proposal
development and approval (Steps 1–3 of the ancillary
study workflow described above and shown in Table 1).
For example, to investigate exceptional responses to a
disease (and inspire therapeutics), investigators may
need to pool the results from many different studies to
identify patterns and notable participants. Less com-
monly, the process of information pooling and integra-
tion (Steps 5–7) may also encompass a broad scope
when results and/or specimens from a large number of
primary studies are selected for reuse in an ancillary
study. An information integration system such as an
ASMS can be particularly helpful for broad-scope sce-
narios by providing a unified view across and access to a
wide range of data and specimens, including external
data sources.
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results from a limited set of studies are aggregated and
integrated for reuse in an ancillary study (Steps 5–7 of
the ancillary study workflow). The narrower the scope,
the greater the variety of tools that can serve as viable
alternatives for cross-study data pooling.Degree of integration
 A tight degree of integration between pooled data is
needed when the results of specific primary studies are
aggregated and integrated with ancillary results for rigor-
ous cross-analysis (Steps 5–7 of the ancillary study
workflow). Tighter pooling may also be desirable during
hypothesis generation and study planning to allow more
powerful and accurate data mining (Steps 1–3). As
discussed earlier (see Steps 5 and 7), tight integration
of pooled data requires careful reconciliation and
standardization to ensure data comparability. An ASMS
can facilitate many aspects of tight data pooling, ranging
from providing data reconciliation tools to pre-empting
the need for reconciliation chores in the first place by fa-
cilitating good data management practices.
 Loose integration of pooled data may be adequate
when summary reports of resource availability are suffi-
cient for hypothesis generation, planning and study ap-
proval (Steps 1–3 of the ancillary study workflow). A
unified information system like an ASMS can make it
easier to automatically generate centralized, live sum-
mary roll-ups that span an organization’s data sources
without manually aggregating data from different reposi-
tories. At the same time, the looser the pooling, the
greater the variety of tools that may be adequate.
Actually achieving cross-study data pooling can beget
further challenges in update consistency and data integ-
rity across primary and ancillary studies. Data updates
may need to flow from a primary study to a child ancil-
lary study when data lock in the primary study occurs
after ancillary study initiation. Repatriation of ancillary
study data to relevant primary studies may be desirable
after ancillary study completion (Step 8 in the ancillary
study workflow). Repatriation can be straightforward
when ancillary data are purely additive to primary data;
however, such updates can be problematic when primary
data have been altered in the ancillary study (e.g.,
corrected as part of improved error detection). Moving
data between studies can produce confusion over which
study is the database of record for which type of data.Discussion
Opportunities and challenges for ASMS use
ASMSs designed around the scenarios described here
can help research organizations overcome the ope-
rational and data management challenges of ancillarystudies. By providing tools for difficult, repetitive, and
complex tasks, ASMSs can lower costs, increase efficien-
cies, produce more accurate results, expand the use of
valuable primary study data, and reduce both expertise
and personnel requirements. For organizations with
extensive existing software systems, introducing an
additional data management system may pose substan-
tial challenges in integration, interoperability, data re-
dundancy and data exchange. This may eventually
motivate incorporation of ASMS features into CTMS
systems; however, having a separate, complementary
ASMS may still make sense for certain organizations.
Our collaborators exemplify users who have found value
in developing ASMSs that are complementary to existing
systems. Key motivators for system development have
been hypothesis generation and specimen allocation for
pre-clinical, not clinical, studies. Their questions have
been exploratory and outside of the FDA pipeline, so they
have not needed or wanted the overhead of working
within a fully validated CTMS. Furthermore, their
in-house software infrastructure did not provide natural
points for integrating ASMS features. Some had arms-
length relationships with the contract research organiza-
tions (CROs) running relevant CTMSs, while others did
not employ comprehensive, integrated CTMSs. For this
reason, direct interoperability of the ASMS system with a
CTMS was not desired or needed.
Even when integration of ASMS features into a CTMS
may be ideal, it may not be practical, so a complemen-
tary ASMS may be desirable. For an organization that
already has a CTMS, updates to the CTMS system can
be nontrivial, particularly when system validation is
required for clinical studies. Furthermore, supporting
the specimen allocation scenarios of ancillary studies
requires some degree of integration with one or several
LIMS, which may not be feasible for a CTMS.
Cross-study scenarios can be key motivators for adop-
ting an ASMS, particularly when an organization already
has a CTMS in place. Cross-study data pooling and inte-
gration scenarios can be problematic for a CTMS given
the paucity of such support in many existing CTMSs.
Furthermore, when ancillary studies need to begin
before data lock of relevant primary studies, an ASMS
may be needed to update and possibly reconcile ancillary
study records with updates from relevant primary
studies.
If an ASMS is used as a complement to existing sys-
tems, interoperability, data exchange and data integra-
tion may be somewhat eased by the further development
and adoption of standards, including standardized onto-
logies. The arrows in Figure 1 suggest many of the po-
tential pain points for data exchange in the workflows
discussed here, including the transmission of: (1) pri-
mary study results from CTMS to ASMS, (2) specimen
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(3) consent information from clinical sites to ASMS or
CTMS (4) specimen requests (including MTAs) from
ASMS to specimen repositories, (5) specimen metadata
from specimen repositories to assay labs, (6) assay
results to ASMS, (7) ancillary study results from ASMS
to CTMS, and (8) ancillary study results from ASMS to
publications or other venues for sharing results. Add-
itional pain points that are not shown include the trans-
fer of (1) case report form (CRF) results to CTMS and
later to ASMS; (2) primary study consent and IRB infor-
mation to CTMS and later to ASMS; and (3) ancillary
study consent and IRB approval to ASMS; and (4) assay
results from laboratory machines to lab record systems.
Data transfer becomes further complicated when up-
stream errors occur and changes need to propagate to
downstream systems, or when quality control mistakes
are identified downstream and need to propagate up-
stream. Even when data exchange succeeds, semantic
variations in delivered data, lack of sufficient data con-
text, and uncertain data provenance can still stymie
comprehension and meaningful use.
Standards relevant to some of these data transfer
and comprehension pain points are already available
(e.g., standards for CRF results [81]), while others are
undergoing continued, active development [72,76-78,82-86].
Widely used standards have the potential to facilitate the re-
use of study data, the automation of ancillary study work-
flows, and even the reuse of software systems themselves.
However, in our experience developing software systems,
systematic use of standards is currently more the exception
than the rule. For this reason, the adoption of standards
cannot be assumed as a uniform solution for many of the
data transfer challenges mentioned here. This may change
as NIH grant requirements drive a greater degree of adher-
ence to standards. For example, the recent funding oppor-
tunity announcements for the competitive renewal of the
HVTN [87], HPTN [88], and MTN [89] require CDISC
[90] compliance for the collection, storage, and transfer of
study data.
While standards do yet provide a complete solution,
some degree of usage of both official standards (such as
CDISC) and pervasive, industry-developed file formats
can still reduce integration hurdles and foster system
adoption. In our experience disseminating the LabKey
Server open source platform, we have found that organi-
zations that use data formats already incorporated in the
platform (e.g., Frontier Science’s LDMS [91] format for
describing specimens and Clinical DataFax System Inc.’s
DataFax [92] format for defining datasets and visit maps)
consider this a plus for adopting LabKey Server. LabKey
Server itself emphasizes well-documented archive for-
mats [93] that convey study data via tab-separated value
text files and metadata, properties, and settings viasimple XML files. A variety of organizations (e.g.,
SCHARP) use these formats to integrate external study
data into their LabKey Server systems. However, we have
seen few industry-defined data formats (or official,
community-defined standards) that are sufficiently
widely used to be significant drivers of adoption and use.
Instead, providing flexibility in accommodating an orga-
nization’s existing or newly invented data types (e.g.,
LabKey Server’s graphical wizard for describing new
assay data types [30]) has proven far more important to
adoption. Our experience squares with a recently pub-
lished comparison of the success factors for i2b2 and
REDCap (Research Electronic Data Capture) and the
hindrances of caBIG (cancer Biomedical Informatics
Grid) [94].Naming considerations
No genuinely standard terminology exists to describe
systems for primary study management, let alone ancil-
lary study management. For example, the term Clinical
Data Management System (CDMS) is sometimes used as
a synonym for CTMS (e.g., Ohmann et al [84].). Given
this variability, we made a best approximation when we
chose the term ASMS. In our own experience, the key
use case for such a system is management of data for
follow-up studies that require analysis of storied speci-
mens. However, we define the term ASMS more broadly,
encompassing both secondary data analysis studies and
studies that require additional measurements (clinical,
specimen-based or both). We expect an ASMS to be
useful in these situations as well.
We derived the name Ancillary Study Management
System based on common terminology and use cases.
During our review of research network protocols, the
term “ancillary studies” came up most frequently and
specifically as the term for follow-up studies that
encompassed more than just secondary data analysis.
The appearance of the term “ancillary studies” in NIH
grant announcement titles [2-9] and the frequency of
this term in PubMed searches [10] (910 hits, as of
December 2012) confirmed that it is in common use.
We define an ASMS as a system for managing data
for follow-up studies. Such studies require collection
of additional measurements, usually from stored spe-
cimens, or secondary analysis of data.Current system development efforts
Given the calls for open source CTMSs in the recent
past [19,24], we expect open source ASMSs to be desi-
rable. In collaboration with CHAVI, the ITN and nPOD,
we are currently developing a general-purpose, open-
source ASMS based on the LabKey Server system. This
paper does not fully explore the ancillary study features
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development.
LabKey Server is a web application implemented in
Java that runs on the Apache Tomcat web server and
stores its data in a relational database engine. It sup-
ports managing, integrating, analyzing and sharing a
wide range of experimental and clinical data types. The
system already includes many features particularly help-
ful for ancillary study data management, including tools
for: (1) sorting, filtering, aligning, and visualizing data;
(2) managing experimental data types; (3) integrating
varied types of data from different sources; (4) marking
columns with ontological concepts to indicate meaning
and relationships; and (5) summarizing and reviewing
available data in real time; and (6) performing quality
control in a traceable manner. The system also already
includes many features useful for operational manage-
ment of ancillary studies, including: (1) role- and
group-based security; (2) specimen tracking and re-
quest management (3) issue trackers; (4) wikis; (5) mes-
sage boards; (6) file management tools; and (7) client
libraries for building custom interfaces. The basic fea-
tures and architecture of LabKey Server are explored
elsewhere [30,32,33].
Current and future development efforts address five
key ancillary study scenarios: (1) sub-setting, tracking,
and pooling participants within studies; (2) reporting
and analysis at the participant group level; (3) scheduling
and tracking expectations; (4) providing data context;
and (5) tracing data provenance. The current LabKey
Server release (v12.3) already provides support for not-
able portions of the first four of these scenarios and a
few cases of the fifth.
Source code, documentation, tutorials and videos for
LabKey Server are freely available under the Apache 2.0
license [95] from the LabKey Software Foundation at
http://www.labkey.org. Stable, installable releases of the
system are freely available from LabKey Software at
http://www.labkey.com. LabKey Server is maintained by
a team of professional software engineers.ASMS design strategies for addressing cross-study
challenges
A well-designed, robust ASMS can help overcome cross-
study challenges, both by providing tools and by facilitating
best practices. As mentioned previously, cross-study scenar-
ios (particularly data aggregation, reconciliation, integration,
and revision) can prove particularly influential in the deci-
sion to adopt an ASMS. To demonstrate the feasibility
of using an ASMS to address such issues, we highlight a
few of the ASMS design strategies we have used in
developing LabKey Server’s ASMS features and in advising
organizations on best practices:1. Emphasize and support data management
strategies that produce standardized, comparable
data. The cleanest way to deal with data
reconciliation challenges is simply to pre-empt them.
This requires a multifaceted approach, including
good data management practices, collaborative
planning, long-term thinking and robust information
systems. For example, establishing common, uniform
vocabularies and ontologies can aid standardization;
however, enforcement may require providing
informatics tools that support vocabulary
specification for data entry.
2. Recognize that human review and judgment are
essential, so make them easier. Automated
methods for combining data may be convenient, but
they are not always justifiable. Human judgment
must still play a role in ensuring that data are
comparable and/or in making data comparable. To
facilitate human judgment, it is helpful to provide
context and provenance information alongside data,
as well as to assist the tracking and collection of this
type of information. For example, LabKey Server
helps users associate protocols with studies, enter
structured metadata alongside experimental data,
associate transformation scripts with imported data,
and tag excluded data with color-coded quality
control flags.
3. Provide tools and strategies for standardizing
and reconciling data in bulk, particularly during
import. Standardizing data during the import
process itself makes it easier to track how and when
the data were transformed, plus avoid identifier
conflicts that would (by design) prevent data import.
LabKey Server supports visit mapping, so visits of the
same type or range of dates can be aliased to the
same canonical visit identifiers. To prevent conflicts
between participant identifiers, our collaborators
often prefix a study identifier before each one to
ensure uniqueness during import to LabKey Server.
To standardize column names, users can specify
column metadata “import aliases” that map to
canonical column headers. Various scripting options
are available for field-by-field transformations. For
example, the system supports the association of a
sequence of scripts with a versioned pipeline that
reproducibly transforms experimental data during
import. To aid verification of expected values,
column metadata can specify validators (e.g., regular
expressions, expected ranges, and type constraints)
that are applied during data import, plus trigger
color coding of invalid or missing data. Other quality
control mechanisms (such as missing value
indicators and quality control states) can further aid
data reconciliation and standardization.
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that it be brought into the ASMS. External data
sources (e.g., a CTMS database or a SAS repository)
can be made directly accessible within a LabKey
Server. This can provide visibility across all available
datasets and facilitate incorporation of external data
into ancillary studies. Access to external data is
dynamic, meaning that any modifications to such data
within an external repository are immediately viewable
on the associated LabKey Server.
5. Provide tools for looking across all available data,
both built-in and custom. LabKey Server’s query
tools support drawing in data from multiple studies
and placing filtered versions of this data into ancillary
studies, as well as displaying summary views. A variety
of common summary dashboards are already built into
LabKey Server. The system also provides full-text
search for many types of data and documents, plus
"study-aware" search for relevant concepts, particularly
participant identifiers and study properties.
6. Support “live updates” of primary study data
contained within an ancillary study. When the
ancillary study is initiated before a primary study is
complete, it may be desirable for changes to the
primary study (including specimen information, such
as location and available vials) to flow automatically
into equivalent datasets in the ancillary study.
However, such automatic updates can make it hard to
know which versions of primary data have been used
in derived materials (such as preliminary figures). To
ameliorate this versioning challenge, a snapshot of the
ancillary study itself may be taken, or the derived
materials may themselves be displayed live on the
server (both options LabKey Server supports). LabKey
Server implements the “live update” option by
requiring that primary study datasets exist separately
from ancillary datasets. This assumption works well for
“freezer studies,” where no new participant visits occur
that might cause extension of primary datasets.
7. Support creating ancillary studies based on
“snapshot” subsets of primary study data. This
option minimizes confusion about which version of
primary study data the ancillary study contains.
Capturing and archiving a study snapshot at a
particular point in time can also provide traceability
and reproducibility when researchers publish on
intermediate results before a study has completed and
locked.
Conclusion
The scenarios and requirements described here can help
guide the development of systems that can make conduct-
ing ancillary studies easier, less expensive and less error
prone. Given the relatively consistent characteristics andchallenges of ancillary study management, general-purpose
ASMSs are likely to be useful to a wide range of organiza-
tions. Open source, general-purpose ASMSs (such as the
one we are developing as part of LabKey Server) are par-
ticularly desirable due to their lack of licensing fees and
openness to customization by individual organizations.
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